http://www.fresenius.com en-us Tue, 14 Jul 2020 00:00:00 +0200 Tue, 14 Jul 2020 00:00:00 +0200 Tue, 14 Jul 2020 08:00:00 +0100 <![CDATA[Fresenius Medical Care in Schweinfurt joins environmental pact of Germany’s Bavaria state]]> Fresenius Medical Care is joining through its Schweinfurt facility a Bavarian government initiative that aims to show how a strong economy is fully compatible with a healthy environment.

]]>
Wed, 08 Jul 2020 08:00:00 +0100 <![CDATA[Fresenius Helios publishes sustainability report]]> Helios Germany has published its first sustainability report. Oriented to the internationally established standards of the Global Reporting Initiative, this 60-page document outlines the four main target groups and areas that Germany’s largest private hospital operator has defined for its sustainability strategy: Patients, employees, the environment and compliance. Along with numerous statistics and examples from Helios Germany hospitals,  the report sets out the company’s goals for its future development. Titled ”Für eine gesunde Zukunft” (toward a healthy future), the report is now available in German on www.helios-gesundheit.de. An English version will be published soon.

]]>
Wed, 08 Jul 2020 08:00:00 +0100 <![CDATA[Fresenius Medical Care holds virtual General Meeting on August 27, 2020 – dividend proposal unchanged ]]> Fresenius Medical Care will hold its Annual General Meeting (AGM) on August 27, 2020 as a virtual event. 

]]>
Wed, 08 Jul 2020 08:00:00 +0100 <![CDATA[Fresenius holds virtual General Meeting on August 28, 2020 – dividend proposal unchanged]]> Fresenius will hold its Annual General Meeting (AGM) on August 28, 2020 as a virtual event. Originally, the AGM was scheduled for May 20, 2020. It had to be postponed due to the coronavirus pandemic.

]]>
Tue, 23 Jun 2020 08:00:00 +0100 <![CDATA[Dr. Sebastian Biedenkopf to succeed Dr. Jürgen Götz on Management Board of Fresenius]]> Dr. Sebastian Biedenkopf will join the Management Board of Fresenius as Chief Legal and Compliance Officer, and Labor Relations Director, no later than January 1, 2021. He will succeed Dr. Jürgen Götz, who is leaving the company at his own request at the end of June.

]]>
Fri, 19 Jun 2020 08:00:00 +0100 <![CDATA[Fresenius Medical Care expands TCU network in the USA]]> Fresenius Medical Care North America intends to open more than 100 new transitional care units (TCUs) this year. These units will help people recently diagnosed with kidney failure learn about the treatment options available to them including home dialysis, and become more empowered in managing their own care. TCUs are designed to be a separate space within a dialysis center with staff dedicated to onboarding patients new to dialysis during their first weeks of treatment, assisting patients transitioning between modalities, and supporting individuals returning to dialysis from transplant. Fresenius Medical Care North America has been rapidly opening TCUs, with a total of 65 operating already, in support of its home growth strategy. The company has found that over 50 percent of TCU patients will choose a home dialysis modality.

]]>
Mon, 15 Jun 2020 08:00:00 +0100 <![CDATA[Fresenius Medical Care expands production at St. Wendel plant in response to higher demand caused by COVID-19 pandemic]]> Fresenius Medical Care has started a new production line for dialysis fluids at its St. Wendel, Germany, plant. The new line for so-called “CiCa solutions” – citrate anticoagulants, which prevent clotting of the blood – is the plant’s fifth production line for dialysis fluids used in the treatment of acute and chronic kidney disease. 

]]>
Mon, 15 Jun 2020 08:00:00 +0100 <![CDATA[Drug from Fresenius Kabi now available in the U.S. after Emergency Use Authorization]]> Following the recent U.S. Food and Drug Administration (FDA) Emergency Use Authorization, Fresenius Kabi Propoven 2% is now available in the U.S. Propoven 2% is a higher concentrated dosage form of propofol compared to Fresenius Kabi’s FDA-approved Diprivan® 1%, providing clinicians with another sedation option for ventilated COVID-19 patients. The higher concentration presentation allows Fresenius Kabi to support more patients through more efficient use of existing manufacturing capacity.

]]>
Fri, 29 May 2020 08:00:00 +0100 <![CDATA[Fresenius Helios acquires hospital in western Germany]]> Fresenius Helios is acquiring the Malteser Hospital (“MKHB”) in the western German city of Bonn. The 400-bed acute care hospital, with approximately 750 employees, treats approximately 13,000 patients annually.

]]>
Thu, 28 May 2020 08:00:00 +0100 <![CDATA[Fresenius Kabi enters marketing agreement for biosimilar product]]> Fresenius Kabi and the pharmaceutical company medac have agreed to cooperate in Germany in the area of treatments for rheumatic illnesses. On June 1, medac’s sales representatives will begin offering the adalimumab biosimilar IDACIO® as an additional therapy option to the rheumatologists and dermatologists they work with. This biosimilar, developed by Fresenius Kabi and launched last year in Europe, is used to treat autoimmune illnesses such as arthritis and psoriasis. medac is a leading provider of methotrexate (metex® PEN, metex® FS) for the parenteral treatment of patients with chronic inflammatory diseases. Since affected patients are often treated with a combination of methotrexate and adalimumab, the partnership between Fresenius Kabi and medac will offer patients and doctors new benefits and synergies in therapy offerings as well as consulting.

]]>
Wed, 27 May 2020 08:00:00 +0100 <![CDATA[Fresenius Kabi’s regulatory submission for pegfilgrastim biosimilar accepted for review by FDA]]> Fresenius Kabi announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company`s Biologics License Application (BLA) for MSB11455, a biosimilar candidate of Neulasta® (pegfilgrastim)*. This is an important achievement in the development of Fresenius Kabi’s biosimilar pipeline in the US. Fresenius Kabi also received acceptance for review of its regulatory submission for its pegfilgrastim biosimilar candidate from the European Medicines Agency this month. (* Neulasta® is a registered trademark of Amgen)

]]>
Fri, 22 May 2020 08:00:00 +0100 <![CDATA[Fresenius Kabi’s regulatory submission for pegfilgrastim biosimilar accepted for review by EMA ]]> The European Medicines Agency (EMA) has accepted for review Fresenius Kabi`s Marketing Authorization Application (MAA) for MSB11455, a biosimilar candidate of Neulasta® (pegfilgrastim)*. This is another milestone for Fresenius Kabi following last year`s approval and launch of the company`s adalimumab biosimilar (Idacio®) in Europe. (* Neulasta® is a registered trademark of Amgen)

]]>
Thu, 21 May 2020 08:00:00 +0100 <![CDATA[Fresenius Medical Care confirms illegal publication of patient data in Serbia subsequent to recent hacker attack]]> Fresenius Medical Care is aware that patient data from some of the company’s dialysis centers in Serbia has been published by unauthorized persons. The company’s understanding is that this is associated with the IT incident which affected parts of Fresenius’s IT environment a few weeks ago and that hackers were able to steal certain data. 

]]>
Tue, 19 May 2020 08:00:00 +0100 <![CDATA[Fresenius Medical Care places bonds with a volume of 1.25 billion euros]]> Fresenius Medical Care today successfully placed bonds in two tranches with an aggregate volume of €1.25 billion.

]]>
Wed, 06 May 2020 08:00:00 +0100 <![CDATA[Fresenius Medical Care posts solid first quarter results underlining resilience of business model]]> Rice Powell, Chief Executive Officer of Fresenius Medical Care, said: “In these unprecedented times, it is our first and foremost priority to maintain the continuity and high quality of care. (…)”

]]>
Wed, 06 May 2020 08:00:00 +0100 <![CDATA[Solid start to 2020 – Fresenius proves its resilience in light of significant COVID-19 effects]]> Stephan Sturm, CEO of Fresenius, said: “The COVID-19 pandemic has created unprecedented challenges for Fresenius. We are doing everything we can to continue providing the best possible care for our patients around the world. (…)”

]]>
Mon, 04 May 2020 08:00:00 +0100 <![CDATA[Fresenius Medical Care enhances home dialysis offering for patients in Europe, Middle East and Africa region]]> Fresenius Medical Care is enhancing its home dialysis offering in the company’s Europe, Middle East and Africa (EMEA) region.

]]>
Wed, 22 Apr 2020 08:00:00 +0100 <![CDATA[Fresenius Helios develops process for safe reuse of masks]]> Fresenius Helios has developed a secure and highly effective process for purifying medical protective masks so they can be safely reused. It is being employed for FFP2- and FFP3-type masks, which help protect medical and care personnel who are treating COVID-19 patients. Going well beyond the safety standard set out by the Robert Koch Institute, Germany’s government agency responsible for disease control and prevention, the process allows the purified masks to be used by any staff member – not just the previous user. Starting immediately, Helios Germany’s hospitals can purify 8,000 masks daily using the process, which was developed with the support of Fresenius Vamed and Fresenius Medical Care. The company has chosen not to commercialize the process and is making complete information about it available online, free of charge.

]]>
Wed, 22 Apr 2020 08:00:00 +0100 <![CDATA[Fresenius Medical Care supplies extra dialysis machines for COVID-19 patients in U.S.]]> Fresenius Medical Care North America is making 150 additional dialysis machines available to U.S. hospitals for the emergency treatment of COVID-19 patients, under the company’s newly established National Intensive Renal Care Reserve. The reserve creates a pool of dialysis machines that can be sent to hospitals on short notice, and nearly doubles the volume of consumables available to perform treatments. The increased demand is a result of many COVID-19 patients requiring renal replacement therapy due to acute kidney injury, and not all hospitals having enough dialysis machines to treat them.

]]>
Mon, 20 Apr 2020 08:00:00 +0100 <![CDATA[Fresenius Helios supports COVID-19 research]]> To obtain and secure important data for research into SARS-CoV 2, Fresenius Helios has established a multi-center COVID-19 register. Since back in February a team of Helios experts, supported by the Brandenburg Medical School outside of Berlin, has been gathering pseudonymized data on patients treated for COVID-19 in Germany. The goal is to develop insights and knowledge for the battle against the new virus. First research findings from the project, which is scheduled to last a year and is financed by Helios, are now being readied for publication.

]]>